- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
Synonyms: SHR-1316
Adebrelimab (Anti-B7-H1 / PD-L1 / CD274) is a humanized immunoglobulin G4 (IgG4) monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1, cluster of differentiation 274, CD274) with promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC). MW: 145.8 kD.
| Name | Citation | PD-1/PD-L1 interaction | PD-1 | PD-L1 | PD-1/PD-L1 | Others |
|---|---|---|---|---|---|---|
| GS-4224 | 0 | |||||
| INCB086550 | 1 | |||||
| BMS-1001 | 0 | |||||
| BMS-1166 | 8 | |||||
| PD-1/PD-L1 Inhibitor 3 | 13 | |||||
| BMS-1 | 13 | |||||
| BMS202 | 26 | |||||
| CA-170 (AUPM-170) | 0 | |||||
| SR 0987 | 1 | IL17,RORγt | ||||
| Spartalizumab (anti-PD-1) | 3 | |||||
| Camrelizumab (anti-PD-1) | 2 | |||||
| AUNP-12 | 3 |
| Description |
Adebrelimab (Anti-B7-H1 / PD-L1 / CD274) is a humanized immunoglobulin G4 (IgG4) monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1, cluster of differentiation 274, CD274) with promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC). MW: 145.8 kD.
|
References |
|---|
| CAS No. | 2247114-85-6 |
|---|---|
| Molecular Weight | 145.8 |
| Isotype | Human IgG4SP |
| Source | CHO |
| Purification | AKTA |
| Sterility | 0.2 μM filtered |
| Formulation | 100 mM Pro-Ac, 20mM Arg, pH5.0 |
| Storage (From the date of receipt) |
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles. |
*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.